102 related articles for article (PubMed ID: 23753921)
1. Molecular pathways: P-Rex in cancer.
Pandiella A; Montero JC
Clin Cancer Res; 2013 Sep; 19(17):4564-9. PubMed ID: 23753921
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells.
Montero JC; Seoane S; Pandiella A
Cell Signal; 2013 Nov; 25(11):2281-9. PubMed ID: 23899556
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of the PTEN:P-Rex2 signaling complex reveals how cancer-associated mutations coordinate to hyperactivate Rac1.
D'Andrea L; Lucato CM; Marquez EA; Chang YG; Civciristov S; Mastos C; Lupton CJ; Huang C; Elmlund H; Schittenhelm RB; Mitchell CA; Whisstock JC; Halls ML; Ellisdon AM
Sci Signal; 2021 May; 14(681):. PubMed ID: 33947796
[TBL] [Abstract][Full Text] [Related]
4. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
5. P-Rex1 and P-Rex2 RacGEFs and cancer.
Srijakotre N; Man J; Ooms LM; Lucato CM; Ellisdon AM; Mitchell CA
Biochem Soc Trans; 2017 Aug; 45(4):963-77. PubMed ID: 28710285
[TBL] [Abstract][Full Text] [Related]
6. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
7. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
8. P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.
Montero JC; Seoane S; Ocaña A; Pandiella A
Oncogene; 2011 Mar; 30(9):1059-71. PubMed ID: 21042280
[TBL] [Abstract][Full Text] [Related]
9. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
Mense SM; Barrows D; Hodakoski C; Steinbach N; Schoenfeld D; Su W; Hopkins BD; Su T; Fine B; Hibshoosh H; Parsons R
Sci Signal; 2015 Mar; 8(370):ra32. PubMed ID: 25829446
[TBL] [Abstract][Full Text] [Related]
10. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Priulla M; Calastretti A; Bruno P; Azzariti A; Paradiso A; Canti G; Nicolin A
Prostate; 2007 May; 67(7):782-9. PubMed ID: 17373720
[TBL] [Abstract][Full Text] [Related]
11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
12. PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer.
Zhang Y; Zhang J; Xu K; Xiao Z; Sun J; Xu J; Wang J; Tang Q
Hepatogastroenterology; 2013 Oct; 60(127):1766-72. PubMed ID: 24624456
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of P-Rex guanine-nucleotide exchange factors.
Lawson CD; Hornigold K; Pan D; Niewczas I; Andrews S; Clark J; Welch H
Small GTPases; 2022 Jan; 13(1):307-326. PubMed ID: 36342857
[TBL] [Abstract][Full Text] [Related]
15. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.
Yang N; Hui L; Wang Y; Yang H; Jiang X
Oncol Rep; 2014 Jun; 31(6):2651-9. PubMed ID: 24700142
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
[TBL] [Abstract][Full Text] [Related]
17. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
19. Genetics and molecular biology of mesothelioma.
Fennell DA
Recent Results Cancer Res; 2011; 189():149-67. PubMed ID: 21479900
[No Abstract] [Full Text] [Related]
20. High glucose-induced hypertrophy of mesangial cells is reversed by connexin43 overexpression via PTEN/Akt/mTOR signaling.
Liu L; Hu X; Cai GY; Lv Y; Zhuo L; Gao JJ; Cui SY; Feng Z; Fu B; Chen XM
Nephrol Dial Transplant; 2012 Jan; 27(1):90-100. PubMed ID: 21633095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
